Liminatus Pharma, Inc. Receives Additional Nasdaq Deficiency Notice; Shareholders to Vote on Reverse Stock Split
Liminatus Pharma, Inc. (NASDAQ: LIMN) has disclosed significant updates regarding its continued listing on the Nasdaq Stock Market, which may have material implications for shareholders and the company’s share price.
Key Points from the 8-K Filing
- Nasdaq Delisting Risk: On January 15, 2026, Liminatus Pharma received a notice from the Nasdaq Listing Qualifications Department stating that the company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1), known as the “Bid Price Rule.” This rule requires listed securities to maintain a minimum bid price of \$1.00 per share over a consecutive 30-business-day period.
- Compliance Period: The company was granted a 180-calendar-day compliance period to regain compliance with the Bid Price Rule.
- Panel Review: The notice clarifies that a decision regarding Liminatus Pharma’s continued listing will be made by a Nasdaq Hearings Panel. The company must present its response regarding the deficiency in writing no later than July 27, 2026. As of the filing date, the Panel had not issued a decision.
- No Assurance of Continued Listing: There is no guarantee that Nasdaq will provide additional time to regain compliance or that the company will be able to meet the minimum bid price requirement in the future.
- Reverse Stock Split Proposal: On July 13, 2026, the company filed a definitive proxy statement for its annual meeting scheduled for August 3, 2026. A key agenda item is to authorize the board of directors to approve a reverse stock split of Liminatus Pharma’s common stock. This action is a common strategy to help companies meet minimum bid price requirements and avoid delisting.
Implications for Shareholders
- Potential for Share Price Volatility: The risk of delisting from Nasdaq is a critical issue for any publicly traded company. Delisting could significantly reduce liquidity and market visibility, possibly leading to a decline in share value.
- Reverse Stock Split: If approved and executed, the reverse stock split could increase the per-share price of LIMN, but it does not change the company’s overall market capitalization. However, reverse splits sometimes signal financial distress, which may affect investor sentiment.
- Uncertainty Regarding Compliance: The company has not assured that it will regain compliance within Nasdaq’s timelines, and there is a risk that Liminatus Pharma could be delisted if it fails to meet the requirements.
- Important Upcoming Date: Shareholders should note the annual meeting on August 3, 2026, as the outcome of the reverse stock split proposal could directly impact the company’s ability to remain listed on Nasdaq.
Other Information
- Emerging Growth Company: Liminatus Pharma is classified as an emerging growth company.
- No Written Communications or Soliciting Material: The company clarified that this filing does not include written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement communications under Rule 14d-2(b) or Rule 13e-4(c).
Forward-Looking Statements
The company cautions investors that forward-looking statements in this report are subject to risks and uncertainties. There is no assurance that Nasdaq will accept any plan to regain compliance, nor that the company will meet Nasdaq listing standards in the future. Actual results may differ materially from those projected, and Liminatus does not undertake to update forward-looking statements except as required by law.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation regarding any securities. Investors should review all filings and consult their financial advisor before making investment decisions. Past performance is not indicative of future results. The information is based on publicly available filings as of July 24, 2026, and is subject to change without notice.
